These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7232826)

  • 41. [Antitumor effect of 1,3,3,5,5-pentaziridino-1-thia-2,4,6-triaza-3,5- diphoshorine-1-oxide].
    Kato T; Takamoto S; Ota K
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3401-7. PubMed ID: 3789752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo immunomodulating properties of two synthetic agents: azimexon and tuftsin.
    Florentin I; Schulz J; Bruley-Rosset M; Kiger N; Martinez J; Mathé G
    Recent Results Cancer Res; 1980; 75():153-61. PubMed ID: 6894500
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of hexaphosphamide on the cellular cycle of mouse lympholeukemia L-1210].
    Egorov LV; Gerasimova NA; Kozinets GI; Zaretskiĭ II
    Probl Gematol Pereliv Krovi; 1976 Mar; 21(3):30-3. PubMed ID: 995892
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase II trial of diaziquone in advanced renal adenocarcinoma.
    Hansen M; Gallmeier WM; Vermorken J; Holdener E; Hansen HH; Renard J; Rozencweig M
    Cancer Treat Rep; 1984; 68(7-8):1055-6. PubMed ID: 6744342
    [No Abstract]   [Full Text] [Related]  

  • 45. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory lymphoma.
    McLaughlin P; Cabanillas F; Bedikian AY; Bodey GP
    Cancer Treat Rep; 1983 May; 67(5):507-8. PubMed ID: 6850666
    [No Abstract]   [Full Text] [Related]  

  • 46. Phase II study of diaziquone in patients with advanced carcinoma of the lung.
    Frytak S; Eagan RT; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984 Sep; 68(9):1193-4. PubMed ID: 6478455
    [No Abstract]   [Full Text] [Related]  

  • 47. Phase I-II diaziquone chemotherapy in brain tumors.
    Madajewicz S; Spaulding M; Bhimani S; Avellanosa A; DeLos Santos R; Perry A; Zeigler P; Kirshner J
    Cancer Treat Rep; 1984 Jun; 68(6):913-4. PubMed ID: 6733706
    [No Abstract]   [Full Text] [Related]  

  • 48. Ciamexon-treatment in endocrine ophthalmopathy.
    Utech C; Wulle KG; Pfannenstiel P; Adam W
    Acta Endocrinol Suppl (Copenh); 1987; 281():342-3. PubMed ID: 3303793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effects of azimexon on interleukin 2 and interleukin 1 production in vitro].
    Song JP; Qian DH
    Zhongguo Yao Li Xue Bao; 1988 Sep; 9(5):468-71. PubMed ID: 3265267
    [No Abstract]   [Full Text] [Related]  

  • 50. Phase II clinical trial of diaziquone in bronchogenic carcinoma.
    Chiuten DF; Umsawasdi T; Dhingra HM; Murphy WK; Spitzer G; Carr DT; Bodey GP; Valdivieso M
    Cancer Treat Rep; 1985; 69(7-8):921-2. PubMed ID: 4016800
    [No Abstract]   [Full Text] [Related]  

  • 51. [On the treatment of hemoblastoses with N-diethyleneimidophosphonyl-N-phenylurea (C 73)].
    Gerhartz H; Staeuber PG
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1965; 83(1):54-61. PubMed ID: 4157882
    [No Abstract]   [Full Text] [Related]  

  • 52. Phase II trial of diaziquone in malignant mesothelioma.
    Eagan RT; Frytak S; Richardson RL; Creagan ET; Nichols WC
    Cancer Treat Rep; 1986 Mar; 70(3):429. PubMed ID: 3955559
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of azimexon (BM 12.531) on mouse granulocyte-macrophage and monocyte-macrophage progenitor cells.
    Jeng JC; McCarthy KF; Chirigos MA; Weiss JF
    Experientia; 1982 Jan; 38(1):132-4. PubMed ID: 7056357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Toxicity of aziridinylbenzoquinone for aerobic and hypoxic cells of a transplanted mouse mammary tumor and interaction of the drug with radiation and adriamycin.
    Tannock I
    Cancer Res; 1983 May; 43(5):2059-62. PubMed ID: 6831436
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II clinical trial of diaziquone in the treatment of patients with epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Slayton RE; Blessing JA; Sutton GP; Homesley HD; Park R
    Cancer Treat Rep; 1986 Feb; 70(2):309-10. PubMed ID: 3948196
    [No Abstract]   [Full Text] [Related]  

  • 56. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung.
    Fuks JZ; Aisner J; Van Echo DA; Levitt M; Ihde DC; Carney D; Wiernik PH
    Am J Clin Oncol; 1983 Apr; 6(2):171-3. PubMed ID: 6299094
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-antitumor activity relationships among quinone derivatives.
    Driscoll JS; Hazard GF; Wood HB; Goldin A
    Cancer Chemother Rep 2; 1974 Apr; 4(2):1-362. PubMed ID: 4856629
    [No Abstract]   [Full Text] [Related]  

  • 58. [Antitumor activity and pharmacological properties of furizil].
    Stukov AN; Kraĭz BO; Aleksandrov VA; Ivin BA; Filov VA
    Vopr Onkol; 1985; 31(5):52-4. PubMed ID: 4013130
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II trials of the single agents baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1987 Sep; 71(9):865-7. PubMed ID: 3476203
    [No Abstract]   [Full Text] [Related]  

  • 60. Synthesis and chemotherapeutic effects of ethyl bis-(2,2-dimethyl)-ethylenamido phosphate. A preliminary report.
    Chmielewicz ZF; Bardos TJ; Munson A; Babbitt HL; Ambrus JL
    J Pharm Sci; 1967 Sep; 56(9):1179-81. PubMed ID: 6049709
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.